14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Aug 03, 2026
KVAC vs TOI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KVAC Captures Overall Composite Edge (58.0 HOLD vs 53.5 HOLD), While TOI Leads 4–1 on Growth & Valuation Pillars
KVAC Overall Winner
6-Pillar Tally: KVAC 1 – 4 TOI (1 Tie)
Matrix Metrics: KVAC 5 – 4 TOI
As of Aug 03, 2026, Keen Vision Acquisition Corporation (KVAC) captures the overall head-to-head institutional edge over The Oncology Institute, Inc. (TOI) on higher Unified Composite conviction (58.0/100 HOLD vs. 53.5/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while TOI wins 4–1 across the 6-pillar growth and valuation breakdown. KVAC trades at $11.51 (N/M Forward P/E, 0.0% operating margin) versus TOI at $5.13 (N/M Forward P/E, -4.4% operating margin).
Growth vs. Quality Trade-Off: KVAC earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. TOI 53.5/100 HOLD) and -0.17β · 76% Vol risk profile, whereas TOI leads top-line expansion (+41.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KVAC vs TOI. Trailing 12-month operating profitability (KVAC 0.0% vs TOI -4.4%) and valuation multiples (KVAC N/M vs TOI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Shell Companies value chain with $73.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
TOI Moat ProfileCyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $506.9M market capitalization and -4.4% operating margin.
OpEx & R&D Reinvestment19.5% of Rev ($106M)
90D Engineering Disclosures0 Published
Investor FAQ KVAC vs TOI Key Questions & Quantitative Answers
As of Aug 03, 2026, Keen Vision Acquisition Corporation (KVAC) captures the overall head-to-head institutional edge over The Oncology Institute, Inc. (TOI) on higher Unified Composite conviction (58.0/100 HOLD vs. 53.5/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while TOI wins 4–1 across the 6-pillar growth and valuation breakdown. KVAC trades at $11.51 (N/M Forward P/E, 0.0% operating margin) versus TOI at $5.13 (N/M Forward P/E, -4.4% operating margin). Growth vs. Quality Trade-Off: KVAC earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. TOI 53.5/100 HOLD) and -0.17β · 76% Vol risk profile, whereas TOI leads top-line expansion (+41.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
TOI leads the Growth & Scale pillar: KVAC posts +0.0% YoY revenue growth and -76.9% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TOI at +41.2% YoY revenue growth and +0.0% YoY earnings growth on $546M TTM revenue (15.1% gross margin, -4.4% operating margin). On trailing 12-month operating scale, KVAC generates N/A in USD-normalized revenue versus $546M for TOI. In operating R&D and SG&A reinvestment, KVAC deploys N/A (0 90-day corporate R&D disclosures) versus 19.5% of Rev ($106M) (0 disclosures) for TOI.
KVAC and TOI trade at balanced relative valuation multiples. KVAC trades at N/M Forward P/E, 88.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TOI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-0.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KVAC (0.0% ROE) versus TOI (-651.7% ROE) capital efficiency.
In options market volatility and institutional positioning, KVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 76% Vol realized risk). By comparison, TOI carries 80.2% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.66β · 73% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 03, 2026. For educational research only; not investment advice.